NO153572C - Analogifremgangsm¨te ved fremstilling av terapeutisk aktiv e 5-(2-(2,3-dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1-h ydroxyethyl)-2-hydroxybenzoesyre-derivater. - Google Patents

Analogifremgangsm¨te ved fremstilling av terapeutisk aktiv e 5-(2-(2,3-dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1-h ydroxyethyl)-2-hydroxybenzoesyre-derivater.

Info

Publication number
NO153572C
NO153572C NO801296A NO801296A NO153572C NO 153572 C NO153572 C NO 153572C NO 801296 A NO801296 A NO 801296A NO 801296 A NO801296 A NO 801296A NO 153572 C NO153572 C NO 153572C
Authority
NO
Norway
Prior art keywords
acid
acid acid
droxyethyl
benzodioxan
ylmethyl
Prior art date
Application number
NO801296A
Other languages
English (en)
Other versions
NO801296L (no
NO153572B (no
Inventor
J Martin Grisar
Original Assignee
Richardson Merrell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Merrell Inc filed Critical Richardson Merrell Inc
Publication of NO801296L publication Critical patent/NO801296L/no
Publication of NO153572B publication Critical patent/NO153572B/no
Publication of NO153572C publication Critical patent/NO153572C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO801296A 1979-05-04 1980-05-02 Analogifremgangsm¨te ved fremstilling av terapeutisk aktiv e 5-(2-(2,3-dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1-h ydroxyethyl)-2-hydroxybenzoesyre-derivater. NO153572C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/036,243 US4206125A (en) 1979-05-04 1979-05-04 5-[2-[(2,3-Dihydro-1,4-benzodioxan-2-ylmethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoic acid derivatives

Publications (3)

Publication Number Publication Date
NO801296L NO801296L (no) 1980-11-05
NO153572B NO153572B (no) 1986-01-06
NO153572C true NO153572C (no) 1986-04-16

Family

ID=21887496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO801296A NO153572C (no) 1979-05-04 1980-05-02 Analogifremgangsm¨te ved fremstilling av terapeutisk aktiv e 5-(2-(2,3-dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1-h ydroxyethyl)-2-hydroxybenzoesyre-derivater.

Country Status (21)

Country Link
US (1) US4206125A (no)
JP (1) JPS55147274A (no)
AT (1) AT369365B (no)
AU (1) AU531739B2 (no)
BE (1) BE883087A (no)
CA (1) CA1148963A (no)
CH (1) CH645372A5 (no)
DE (1) DE3014738A1 (no)
DK (1) DK154503C (no)
ES (1) ES8104997A1 (no)
FR (1) FR2455598A1 (no)
GB (1) GB2051780B (no)
IE (1) IE49564B1 (no)
IL (1) IL59681A (no)
IT (1) IT1127441B (no)
NL (1) NL8002208A (no)
NO (1) NO153572C (no)
NZ (1) NZ193236A (no)
PH (1) PH15963A (no)
SE (1) SE434745B (no)
ZA (1) ZA801603B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204285B (en) * 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
JP2931986B2 (ja) * 1989-02-17 1999-08-09 武田薬品工業株式会社 アラルキルアミン誘導体
ES2291733T3 (es) * 2002-10-22 2008-03-01 Glaxo Group Limited Compuestos de ariletanolamina medicinales.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054104A (no) * 1962-07-20
US3514465A (en) * 1966-12-30 1970-05-26 Degussa Certain thiazolyl- and pyridinylaminoketones
US3883560A (en) * 1973-07-05 1975-05-13 Colgate Palmolive Co Salicylamidophenethanolamines
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS55124742A (en) * 1979-03-20 1980-09-26 Kyowa Hakko Kogyo Co Ltd Novel aminoalcohol derivative

Also Published As

Publication number Publication date
IL59681A0 (en) 1980-06-30
CA1148963A (en) 1983-06-28
NO801296L (no) 1980-11-05
CH645372A5 (de) 1984-09-28
AT369365B (de) 1982-12-27
AU531739B2 (en) 1983-09-01
IT8048373A0 (it) 1980-04-09
IE49564B1 (en) 1985-10-30
ES490814A0 (es) 1981-05-16
IE800572L (en) 1980-11-04
FR2455598B1 (no) 1983-05-27
SE8003243L (sv) 1980-11-05
DE3014738A1 (de) 1980-11-13
AU5707780A (en) 1980-11-06
ZA801603B (en) 1981-03-25
GB2051780A (en) 1981-01-21
DK154503C (da) 1989-04-10
JPS642115B2 (no) 1989-01-13
FR2455598A1 (fr) 1980-11-28
NZ193236A (en) 1982-09-14
GB2051780B (en) 1982-12-22
DE3014738C2 (no) 1989-08-03
NL8002208A (nl) 1980-11-06
ATA232780A (de) 1982-05-15
BE883087A (fr) 1980-09-01
DK193580A (da) 1980-11-05
DK154503B (da) 1988-11-21
PH15963A (en) 1983-05-04
IT1127441B (it) 1986-05-21
SE434745B (sv) 1984-08-13
ES8104997A1 (es) 1981-05-16
IL59681A (en) 1984-04-30
NO153572B (no) 1986-01-06
US4206125A (en) 1980-06-03
JPS55147274A (en) 1980-11-17

Similar Documents

Publication Publication Date Title
NO153136C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive naftyridinderivater.
NO154964C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive piperidinderivater.
NO158540C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-penem-forbindelser.
NO153135C (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme n-(fenoksyalkyl)-imidazolderivater.
NO792787L (no) Fremgangsmaate ved fremstilling av antiinflammatorisk aktive 4,5-diaryl-2-nitroimidazoler
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO152841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nye 4-aroylimidazol-2-oner.
NO155055C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-carboxylsyrederivater.
NO152091C (no) Analogifremgangsmaate ved fremstilling av antiinflammatorisk virksomme 5-substituerte 2,3-difenylthiofener
NO164097C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-hetero-aryl-tiazol-derivater.
NO153569C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive merkaptoacetyl-prolin-derivater.
NO166320C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrazolderivater.
NO149312C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2-(2-tenoyltio)-propionylglycin
NO150360C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive merkaptoacyldipeptider
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO154426C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive trans-3-(4-okso-4h-kinazolin-3-yl)-2-propensyrederivater.
NO164472C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte 2-(monokondenserte (3,4- og 5,6)-pyridylalkylensulfinyl)-benzimidazoler.
NO166863C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituert-1,2-dihydro-3h-pyrrolo-(1,2-a)-pyrrol-1-carboxylsyrer ut fra deres tilsvarende nitriler.
NO154268C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 6alfa-flour-9a-klor-prednisolon-17,21-diestere.
NO155137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av 2-(4-piperidyl)-1-(4-kinolyl)-etanon.
NO153572C (no) Analogifremgangsm¨te ved fremstilling av terapeutisk aktiv e 5-(2-(2,3-dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1-h ydroxyethyl)-2-hydroxybenzoesyre-derivater.
NO154396C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive halovincamonderivater.
NO154795C (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1,2,4-oxadiazolin-5-on-derivater.
NO152697C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5-(klorfenyl)-6h-1,3,4-thiadiazin-2-aminer.
NO164095C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av 3-(3-substituerte-amino-2-hydroksypropoksy)-4-substituerte-1,2,5-tiadiazolderivater.